Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump

2026-02-21 03:35:52

Abstract generation in progress

Biogen (NASDAQ:BIIB) reported better-than-expected fourth-quarter earnings and revenues, with Q4 adjusted EPS of $1.99 beating the consensus of $1.59, and revenues of $2.28 billion surpassing estimates. The company’s Alzheimer’s drug Leqembi saw significant growth in collaboration revenue, and Biogen shares reached a new 52-week high after the announcement. Despite declines in multiple sclerosis and rare disease revenue, growth products like Skyclarys and Zurzuvae performed strongly.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.